Free Trial

Achieve Life Sciences (ACHV) Competitors

Achieve Life Sciences logo
$2.68 -0.02 (-0.74%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$2.68 +0.00 (+0.19%)
As of 07/25/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ACHV vs. RIGL, XOMA, VNDA, VSTM, CDXS, CBIO, AGEN, IRWD, SGMO, and DOMH

Should you be buying Achieve Life Sciences stock or one of its competitors? The main competitors of Achieve Life Sciences include Rigel Pharmaceuticals (RIGL), XOMA Royalty (XOMA), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Codexis (CDXS), Crescent Biopharma (CBIO), Agenus (AGEN), Ironwood Pharmaceuticals (IRWD), Sangamo Therapeutics (SGMO), and Dominari (DOMH). These companies are all part of the "biotechnology" industry.

Achieve Life Sciences vs. Its Competitors

Rigel Pharmaceuticals (NASDAQ:RIGL) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

Rigel Pharmaceuticals has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500.

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 9.5% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 3.0% of Achieve Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Rigel Pharmaceuticals has higher revenue and earnings than Achieve Life Sciences. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rigel Pharmaceuticals$203.08M1.78$17.49M$2.079.74
Achieve Life SciencesN/AN/A-$39.83M-$1.34-2.00

Rigel Pharmaceuticals currently has a consensus target price of $36.40, suggesting a potential upside of 80.47%. Achieve Life Sciences has a consensus target price of $14.33, suggesting a potential upside of 434.83%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Achieve Life Sciences is more favorable than Rigel Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rigel Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40
Achieve Life Sciences
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
3.50

Rigel Pharmaceuticals has a net margin of 18.31% compared to Achieve Life Sciences' net margin of 0.00%. Achieve Life Sciences' return on equity of -176.11% beat Rigel Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Rigel Pharmaceuticals18.31% -655.26% 24.47%
Achieve Life Sciences N/A -176.11%-103.32%

In the previous week, Rigel Pharmaceuticals had 1 more articles in the media than Achieve Life Sciences. MarketBeat recorded 3 mentions for Rigel Pharmaceuticals and 2 mentions for Achieve Life Sciences. Rigel Pharmaceuticals' average media sentiment score of 1.63 beat Achieve Life Sciences' score of 0.93 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rigel Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Achieve Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Rigel Pharmaceuticals beats Achieve Life Sciences on 10 of the 15 factors compared between the two stocks.

Get Achieve Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACHV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACHV vs. The Competition

MetricAchieve Life SciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$93.65M$2.49B$5.70B$9.50B
Dividend YieldN/A1.65%4.58%4.01%
P/E Ratio-2.009.1828.4120.08
Price / SalesN/A611.32432.3189.32
Price / CashN/A165.2136.2258.56
Price / Book4.395.168.675.88
Net Income-$39.83M$30.99M$3.25B$258.89M
7 Day PerformanceN/A7.73%4.25%3.71%
1 Month Performance-23.65%16.27%10.51%11.72%
1 Year Performance-45.58%-1.88%35.68%18.01%

Achieve Life Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACHV
Achieve Life Sciences
2.8069 of 5 stars
$2.68
-0.7%
$14.33
+434.8%
-45.2%$93.65MN/A-2.0020
RIGL
Rigel Pharmaceuticals
3.2002 of 5 stars
$19.35
+2.5%
$36.40
+88.1%
+85.0%$345.78M$179.28M9.35160Positive News
XOMA
XOMA Royalty
4.0149 of 5 stars
$27.76
+2.3%
$69.50
+150.4%
-10.7%$332.20M$13.05M-24.1410News Coverage
Analyst Upgrade
VNDA
Vanda Pharmaceuticals
4.7375 of 5 stars
$4.97
+4.9%
$16.50
+232.0%
-22.9%$292.90M$201.35M-6.63290Upcoming Earnings
VSTM
Verastem
3.5303 of 5 stars
$4.96
+6.0%
$13.38
+169.7%
+106.7%$272.55M$10M-1.5550
CDXS
Codexis
3.459 of 5 stars
$3.07
+2.7%
$11.00
+258.3%
-14.8%$254.35M$59.35M-3.10250News Coverage
Positive News
CBIO
Crescent Biopharma
3.2028 of 5 stars
$12.80
-1.2%
$25.67
+100.5%
N/A$250.24M$10K-0.2850Gap Up
High Trading Volume
AGEN
Agenus
4.219 of 5 stars
$6.83
-3.3%
$14.00
+105.0%
-0.1%$187.26M$99.52M-0.79440Positive News
IRWD
Ironwood Pharmaceuticals
4.3673 of 5 stars
$0.74
-1.9%
$4.78
+548.1%
-88.0%$119.44M$351.41M-3.69220Positive News
SGMO
Sangamo Therapeutics
2.3932 of 5 stars
$0.50
+1.6%
$4.50
+800.0%
-12.9%$116.59M$57.80M-1.28480Positive News
DOMH
Dominari
1.0874 of 5 stars
$5.35
+7.2%
N/A+181.1%$78.35M$24.89M-1.194

Related Companies and Tools


This page (NASDAQ:ACHV) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners